ENTA Enanta Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ENTA

Price (delayed)

$11.95

Market cap

$348.05M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.42

Enterprise value

$370.29M

?
Relative Growth: Rel. Growth: 20
Relative Strength: Rel. Strength: 50
Relative Valuation: Rel. Valuation: 12
Relative Profitability: Rel. Profitability: 40

Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs with an emphasis on indications in ...

Highlights
The EPS has grown by 44% year-on-year and by 7% since the previous quarter
The debt has contracted by 4.1% YoY
ENTA's net income is up by 31% year-on-year but it is down by 2% since the previous quarter
The equity has increased by 27% YoY but it has decreased by 13% from the previous quarter
Enanta Pharmaceuticals's quick ratio has decreased by 24% YoY
Enanta Pharmaceuticals's revenue has decreased by 6% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.enanta.com
Peers: VRTX JNJ ABBV MRK

Key stats

What are the main financial stats of ENTA

ENTA stock price

How has the Enanta Pharmaceuticals stock price performed over time
Intraday
-3.78%
1 week
-5.91%
1 month
-11.28%
1 year
66.67%
YTD
-24.22%
QTD
-18.04%

Financial performance

How have Enanta Pharmaceuticals's revenue and profit performed over time
Revenue
$65.26M
Gross profit
$65.26M
Operating income
-$58.73M
Net income
-$63.23M
Gross margin
100%
Net margin
-96.9%
The operating margin has grown by 40% YoY but it has contracted by 3.2% from the previous quarter
The company's operating income rose by 39% YoY and by 2.7% QoQ
The net margin has grown by 32% YoY but it has contracted by 8% from the previous quarter
ENTA's net income is up by 31% year-on-year but it is down by 2% since the previous quarter

Price vs fundamentals

How does ENTA's price correlate with its fundamentals

Growth

What is Enanta Pharmaceuticals's growth rate over time

Valuation

What is Enanta Pharmaceuticals stock price valuation
P/E
N/A
P/B
3.44
P/S
5.33
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.67
The EPS has grown by 44% year-on-year and by 7% since the previous quarter
ENTA's P/B is 37% above its 5-year quarterly average of 2.6 but 3.5% below its last 4 quarters average of 3.7
The equity has increased by 27% YoY but it has decreased by 13% from the previous quarter
The price to sales (P/S) is 22% lower than the 5-year quarterly average of 7.1
Enanta Pharmaceuticals's revenue has decreased by 6% from the previous quarter

Efficiency

How efficient is Enanta Pharmaceuticals business performance
The return on sales has grown by 42% year-on-year but it has declined by 3.4% since the previous quarter
ENTA's return on invested capital is up by 40% year-on-year and by 2.2% since the previous quarter
Enanta Pharmaceuticals's return on equity has increased by 31% YoY and by 3.4% QoQ
Enanta Pharmaceuticals's ROA has increased by 24% YoY but it has decreased by 2.5% from the previous quarter

Dividends

What is ENTA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ENTA.

Financial health

How did Enanta Pharmaceuticals financials performed over time
The company's total assets is 52% higher than its total liabilities
Enanta Pharmaceuticals's current ratio has decreased by 25% YoY and by 2.1% from the previous quarter
Enanta Pharmaceuticals's quick ratio has decreased by 24% YoY
The debt is 45% less than the equity
The equity has increased by 27% YoY but it has decreased by 13% from the previous quarter
The company's debt to equity fell by 25% YoY but it rose by 15% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.